Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.35 |
| ▸ | BTK | Q06187 | 10/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29340562 | 0.91 | CFD (0.41) | EGFRBTKCFDERBB2IGF1R | |
| SCHEMBL29345863 | 0.88 | CFD (0.36) | CFDRETKDR | |
| SCHEMBL29121970 | 0.87 | CFD (0.37) | EGFRBTKCFD | |
| SCHEMBL29346359 | 0.84 | CFD (0.36) | CFD | |
| SCHEMBL29122913 | 0.83 | CFD (0.43) | EGFRBTKCFDERBB2IGF1R | |
| SCHEMBL29122413 | 0.81 | CFD (0.43) | EGFRBTKCFDERBB2IGF1R | |
| SCHEMBL29340566 | 0.81 | CFD (0.40) | EGFRBTKCFDERBB2IGF1R | |
| SCHEMBL29122676 | 0.81 | CFD (0.43) | EGFRBTKCFDERBB2IGF1R | |
| SCHEMBL29121925 | 0.80 | CFD (0.44) | EGFRCFDERBB2IGF1R | |
| SCHEMBL30676378 | 0.79 | CFD (0.44) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | EGFR 2168/4885BTK 2885/4885CFD 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.